Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 assays facilitate care for central nervous system disorders triggered by cancer. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

(00:32)
 Could you tell us a bit about your background and your role at Mayo Clinic?

(01:26)
 How do the tests that are coming live relate to the larger disease state of neurological disorders?

(02:44)
 Can you share a little bit about the methodology we're using for these particular biomarkers? 

(05:15)
 How was PDE10A discovered?

(06:48)
 Anything you would add?

(07:50)
 Remind us which phenotype-specific assays these biomarkers are being added to, and how physicians should determine whether this testing is appropriate?

(09:55)
 What does early detection of these biomarkers mean for the patient's prognosis, diagnosis, treatment, etc.?

(12:33)
 What are you most excited about with the launch of these tests?